Going from stealth to a $150 million series B in five months may seem fast, but, for Rapport Therapeutics, 10 years of toiling in the labs at Johnson & Johnson beforehand helped the neurological ...
A phase 2a trial of Rapport Therapeutics’ focal onset seizure drug candidate has hit its primary endpoint, sending shares in the biotech up more than 157% in premarket trading. The study enrolled 30 ...
BOSTON and SAN DIEGO, June 12, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small ...
Rapport Therapeutics, Inc.'s RAP-219 delivered impressive Phase 2a results in drug-resistant focal onset seizures, driving Rapport Therapeutics' stock up over 135% and boosting investor optimism. The ...
Rapport Therapeutics, a young biotech company with technology from the labs of Johnson & Johnson, is now preparing to enter the public markets to finance clinical research for a lead program that ...
According to professional speaker, consultant and founder of Cause Matters Corp Michele Payn-Knoper, building rapport with customers is critical to showing them "you're sincerely interested in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback